Biosency was created in 2017. Since then, the company has won numerous awards (including I-Nov and I-Lab), integrated experimental program such as E-Meuse and collaborated with pharmaceutical laboratories. Several clinical studies are in progress or to come (some in partnership with Paris Hospitals). To guarantee its deployment, our solution was designed from the beginning to be able to interface with third-party platforms. The long-term objective of Biosency is to offer a predictive medicine solution (COPD exacerbation).